SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

$SOPH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $SOPH alert in real time by email

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine

BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

To advance the adoption of precision oncology, it is crucial to have access to large-scale data from a wide range of modalities (such as imaging, genomics, pathology and clinical notes), and diverse set of patient profiles. Currently, no single institution globally collects the necessary volume and diversity of information to propel the healthcare field forward. SOPHiA GENETICS has launched SOPHiA UNITY to answer that need and meet the demand for high-quality, diverse data at scale, aiming to drive a new era of precision oncology research.

The collective intelligence network will advance research initiatives using SOPHiA CarePath™, the multimodal module on the SOPHiA DDM™ Platform, to aggregate and analyze complex real-world data. This data will be harmonized and curated using SOPHiA GENETICS' advanced AI-based technology and proprietary algorithms. Through SOPHiA GENETICS' unique platform and CarePath™ offering, SOPHiA UNITY members will have access to meaningful, data-driven insights that will support decision-making and expedite oncology research.

"At SOPHiA GENETICS, we have mastered the challenge of harmonizing and connecting genomic data and have the capabilities to do the same with other modalities through our CarePath™ module," said Jurgi Camblong, PhD., Co-founder and CEO of SOPHiA GENETICS. "SOPHiA UNITY will usher in the next era of precision medicine innovation by bringing together best-in-class institutions that are committed to the advancement of oncology research and the use of data-driven medicine. We are extremely optimistic about the insights this collective intelligence network will generate to further our shared goal."

SOPHiA GENETICS announced that the first member to join SOPHiA UNITY is Memorial Sloan Kettering Cancer Center, a top cancer treatment and research institution and world leader in patient care, research, and educational programs. Additional members will be announced in the coming months.

"I am looking forward to participating in the new data-driven consortium and partnering with other institutions to draw deeper insights from our collective data," said Mrinal Gounder, M.D., Sarcoma Oncologist & Early Drug Development Specialist and Physician Ambassador to India and Asia, Memorial Sloan Kettering Cancer Center.

Leading academic cancer centers who are looking to connect with like-minded researchers globally are eligible to join the SOPHiA UNITY collective intelligence network and gather insights that can be implemented locally. For more information, visit SOPHiAGENETICS.COM, or connect on LinkedIn

About SOPHiA GENETICS

SOPHiA GENETICS (NASDAQ:SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: 

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-global-consortium-sophia-unity-to-accelerate-cancer-research-drug-development-and-data-driven-patient-care-302159680.html

SOURCE SOPHiA GENETICS

Get the next $SOPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SOPH

DatePrice TargetRatingAnalyst
12/18/2024$11.00Buy
Craig Hallum
8/7/2024$10.00 → $5.00Overweight → Equal-Weight
Morgan Stanley
6/27/2024$6.00Buy
Guggenheim
11/29/2023$8.00Outperform
RBC Capital Mkts
7/5/2023$10.00Overweight
JP Morgan
1/3/2023$6.00Buy
BTIG Research
11/23/2022$2.00Neutral
Credit Suisse
2/15/2022$23.00 → $18.00Overweight
Morgan Stanley
More analyst ratings

$SOPH
Press Releases

Fastest customizable press release news feed in the world

See more
  • SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC

    BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data. "When we announced one million profiles analyzed in 2022, it was a la

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

    BOSTON and ROLLE, Switzerland, March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectivelyOperating loss was $17.4 m

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

    SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.

    $AZN
    $SOPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$SOPH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SOPH
SEC Filings

See more

$SOPH
Leadership Updates

Live Leadership Updates

See more
  • SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

    BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

    New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

    Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology

    $SOPH
    $XYL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Fluid Controls
    Industrials

$SOPH
Financials

Live finance-specific insights

See more
  • SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

    BOSTON and ROLLE, Switzerland, March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectivelyOperating loss was $17.4 m

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025

    BOSTON and ROLLE, Switzerland, Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally,

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SOPHiA GENETICS Reports Third Quarter 2024 Results

    Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-yearGross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72.5% in the prior year period, respectivelyOperating loss was $15.4 milli

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SOPH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more